ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2130

Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
Abstract Number: 1486

Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Abstract Number: 0615

Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Abstract Number: 0709

Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Abstract Number: 1546

Tacrolimus Versus Voclosporin for Active Lupus Nephritis: A Comparative Meta-analysis of Renal Response
Abstract Number: 2662

Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease
Abstract Number: 1790

Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
Abstract Number: 2165

Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
Abstract Number: 0685

Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Abstract Number: 1760

Targeting the Female-biased Factor VGLL3 in Cutaneous and Systemic Lupus
Abstract Number: 1876

Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts
Abstract Number: 0678

Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Abstract Number: 2461

Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
Abstract Number: 0888

TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis
Abstract Number: 0055

TCR Signaling Thresholds Govern Anergy and Tolerance in ZAP70 Hypomorphic Models of Autoimmune Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].